405230-90-2

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Chloro-5-fluoro-3-nitro-4-pyridinamine is utilized as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
2-Chloro-5-fluoro-3-nitro-4-pyridinaMine also serves as an intermediate in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used as a Building Block in Organic Synthesis:
Due to its reactive functional groups, 2-Chloro-5-fluoro-3-nitro-4-pyridinamine is employed as a building block in organic synthesis. It can be used to construct more complex organic molecules for various applications in the chemical industry.
Used in Medicinal Chemistry Research:
Owing to its intriguing chemical and biological properties, 2-Chloro-5-fluoro-3-nitro-4-pyridinamine has potential applications in medicinal chemistry research. It can be further modified and studied to explore its potential as a therapeutic agent or a chemical probe in understanding biological processes.

Upstream product

• 405230-80-0 2-chloro-5-fluoro-4-nitropyridine-1-oxide 
• 89510-90-7 4-amino-2-chloro-5-fluoropyridine 
• 405230-79-7 2-chloro-5-fluoropyridine-1-oxide 
• 31301-51-6 2-chloro-5-fluoropyridine 
• 405230-86-6 2-chloro-5-fluoro-4-nitraminopyridine 

Downstream Products

• 1334411-83-4 4-bromo-2-(2,6-dichlorophenyl)-7-fluoro-1H-imidazo[4,5-c]pyridine 
• 1334411-84-5 4-chloro-7-fluoro-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine 
• 1334407-23-6 N-(2-(2,6-dichlorophenyl)-7-fluoro-1H-imidazo[4,5-c]pyridin-4-yl)cyclopropanecarboxamide 
• 1334407-22-5 2-(2,6-dichlorophenyl)-N-(2,6-dimethylpyrimidin-4-yl)-7-fluoro-1H-imidazo[4,5-c]pyridin-4-amine 
• 405231-08-5 4-chloro-7-fluoro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridine 
• 405230-97-9 4-chloro-7-fluoro-1H-imidazo[4,5-c]pyridine 
• 202806-40-4 3-deaza-3-fluoro-adenosine 
• 405230-93-5 2-chloro-3,4-diamino-5-fluoropyridine 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy

Novel substituted purine isosters, were designed and synthesized as potential inhibitors of the Epidermal Growth Factor Receptor (EGFR). The compounds were rationally designed through bioisosteric replacement of the central quinazoline core of lapatinib, an approved drug that inhibits both EGFR and HER2, another important member of this family of receptors. The new target molecules were evaluated as inhibitors of receptor phosphorylation at the cellular level, for their direct inhibitory action on the intracellular receptor kinase domain and for their cytotoxicity against the non-small cell lung cancer cell line A549 and breast cancer HCC1954, cell lines which are associated with overexpression of EGFR and HER2, respectively. The most potent derivatives were further studied for their cellular uptake levels and in vivo pharmacokinetic properties. One compound (23)displayed a noteworthy pharmacokinetic profile, and higher intracellular accumulation in comparison to lapatinib in the A549 cells, possibly due to its higher lipophilicity. This lead compound (23)was assessed for its efficacy in an EGFR positive xenograft model, where it successfully inhibited tumor growth, with a similar efficacy with that of lapatinib and with minimal phenotypic toxicity.

IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

The invention provides compounds of Formulas Ia-Ib, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4, R5 and R16 are defined herein, a pharmaceutical composition that includes a compound of Formulas Ia-Ib and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy.

Novel nucleosides and related processes, pharmaceutical compositions and methods

The invention provides novel nucleosides and related processes, pharmaceutical compositions, and methods. The novel nucleosides are useful in a wide variety of antiviral, antineoplastic, and antibacterial applications. Preferred embodiments of the instant invention include novel 2 halogen-substituted, 3 halogen-substituted, and 2′,3′dihalogen-substituted analogues of 3-deazaadenosine, and novel 3 halogen-substituted analogues of 3-deazaguanosine. Compounds of the instant invention, including 4-Amino-6-fluoro-1-(β-D-ribofuranosyl)imidazo[4,5-c]pyridine and 6-Amino-7-bromo-1,5-dihydro-1-β-D-ribofuranosylimidazo[4,5-c]pyridin-4-one, have exhibited potent antiviral and anticancer activity in vitro. The compounds are also useful in the concomitant treatment of bacterial infections associated with viral infections such as AIDS.

Synthesis of halogen-substituted 3-deazaadenosine and 3-deazaguanosine analogues as potential antitumor/antiviral agents

Various 2-halogen-substituted analogues (38, 39, 43 and 44), 3-halogensubstituted analogues (51 and 52), and 2′,3′ -dihalogen- substituted analogues (57-60) of 3-deazaadenosine and 3-halogen-substituted analogues (61 and 62) of 3-deazaguanosine have been synthesized as potential anticancer and/or antiviral agents. Among these compounds, 3-deaza-3-bromoguanosine (62) showed significant cytotoxicity against L1210, P388, CCRF-CEM and B16F10 cell lines in vitro, producing IC50 values of 3, 7, 9 and 7μM, respectively. Several 3-deazaadenosine analogues (38, 51, 57 and 59) showed moderate to weak activity against hepatitis B virus.